Close Menu

More articles about Business, Policy & Funding

Myriad's revenues rose sharply, but the firm fell short of analysts' consensus estimate.

The company plans to use the $417,000 grant to develop assays for monitoring drug interactions.

Nearly all of Exact Sciences' revenues came from license fees, as the firm continues to develop its assay for colorectal cancer.

Link will make and market reagents using RiboTask's UNA monomer technology.

A US district court decided this week that the lawsuit challenging the legality and constitutionality of BRCA gene patents owned by the University of Utah and exclusively licensed to Myriad has sufficient merit to be heard.

The guidance document is intended to help manufacturers develop diagnostic tests for the 2009 H1N1 influenza virus, and provides information regarding filing for Emergency Use Authorization.

On-Q-ity is developing a cancer diagnostic platform that combines monitoring DNA repair biomarkers to predict treatment response and microfluidic chips that enable the capture, enumeration, and characterization of circulating tumor cells in a patient's bloodstream.

Sigma-Aldrich will manufacture and sell the French company's oligonucleotides worldwide.

The FDA cleared the firm's microarray-based multiplex platform and a rheumatoid arthritis test that runs on the system.

Revenues rose slightly as clinical diagnostic sales offset weakness in its blood screening business.

The firm will use Medical Therapies' midkine patent portfolio to develop lung cancer diagnostics.

A 29 percent increase in life science revenues offset weakness in kit sales for water testing.

The licensing of technology by universities to companies added as much as $187 billion to the US gross national product and $457 billion to US gross industrial output, and created nearly 300,000 new jobs from 1996 to 2007, according to the report.

The company will use the investment from MP Healthcare Venture Management to develop its heart failure biomarker program.

The lawsuit claims Nanosphere has infringed Eppendorf's patent covering its Silverquant microarray technology.

Though its Berkeley HeartLab business continued to struggle, Celera CEO Kathy Ordoñez said the firm made progress in addressing some key issues affecting its financial performance.

The patent, No. 4354633, is entitled "Hypoxia-Regulated Genes," and claims various aspects of the RTP801 gene, including inhibitors targeting either the mRNA or peptide products of the gene, Quark said.

The deal will allow Koken to manufacture and sell siRNA research products covered by certain of Alnylam's RNAi-related intellectual property.

IP Update: Oct 29, 2009


USPTO Publishes Two Patents, Eleven Patent Applications Related to RNAi

Cepheid beat analysts' estimates on the top and bottom line, partially due to lower R&D spending.


Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.